Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 16/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.43 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21914803 | 0.81 | PRMT5 (0.52) | PRMT5PTGESALOX5LTC4SIKBKE | |
| SCHEMBL21914579 | 0.79 | PRMT5 (0.52) | PRMT5PTGESALOX5LTC4SIKBKE | |
| SCHEMBL21889198 | 0.78 | PRMT5 (0.57) | PRMT5PTGESALOX5LTC4SIKBKE | |
| SCHEMBL21889308 | 0.77 | PRMT5 (0.47) | PRMT5DHODHPTGESALOX5LTC4S | |
| SCHEMBL21889009 | 0.76 | AOC3 (0.70) | — | |
| SCHEMBL23590409 | 0.72 | PRMT5 (0.45) | PRMT5DHODHPTGESALOX5LTC4S | |
| SCHEMBL21914562 | 0.72 | PRMT5 (0.49) | PRMT5DHODHPTGESALOX5LTC4S | |
| SCHEMBL25836249 | 0.72 | IKBKE (0.50) | PRMT5DHODHPTGESALOX5LTC4S | |
| SCHEMBL21914810 | 0.71 | PRMT5 (0.46) | PRMT5DHODHPTGESALOX5LTC4S | |
| SCHEMBL21914361 | 0.70 | CHEK2 (0.56) | PRMT5DHODHIKBKE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3626699-B1 | SSAO INHIBITOR | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2023-07-12 | — | — | EP | disclosed |
| US-20210198220-A1 | SSAO INHIBITOR | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2021-07-01 | — | — | US | disclosed |
| US-11001563-B2 | SSAO inhibitor | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2021-05-11 | — | — | US | disclosed |
| US-20200115352-A1 | SSAO INHIBITOR | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. | 2020-04-16 | — | — | US | disclosed |
| EP-3626699-A1 | SSAO INHIBITOR | Shandong Danhong Pharmaceutical Co., Ltd. (CN) | 2020-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001563-B2 | SSAO inhibitor | SSB, ASAH2, AOX1 | PRMT5 3044/4885DHODH 80/4885PTGES 582/4885 |
| US-20210198220-A1 | SSAO INHIBITOR | SSB, ASAH2, AOX1 | PRMT5 3044/4885DHODH 80/4885PTGES 582/4885 |
| US-20200115352-A1 | SSAO INHIBITOR | SSB, ASAH2, AOX1 | PRMT5 3044/4885DHODH 80/4885PTGES 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.